论文信息 - Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis - 字舞流文

Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis

R. Latagliata | A. Cuneo | M. Krampera | C. Bosi | F. Heidel | F. Pane | N. Vianelli | G. Caocci | M. Breccia | M. Cavo | M. Tiribelli | M. Bonifacio | A. Iurlo | B. Martino | G. Palumbo | N. Pugliese | G. Semenzato | E. Abruzzese | G. Benevolo | F. Cavazzini | R. Lemoli | G. Binotto | L. Scaffidi | D. Cattaneo | R. Stella | M. Crugnola | F. Palandri | M. Bergamaschi | E. Elli | A. Isidori | A. Tieghi | M. Trawinska | N. Polverelli | G. Auteri | D. Bartoletti | Fiorella Ciantia

[1] M. Griesshammer,et al. Primary analysis of JUMP, a phase 3b, expanded‐access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts , 2020, British journal of haematology.

[2] R. Foà,et al. Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis , 2019, Cancer.

[3] M. Breccia,et al. The role of allogeneic stem-cell transplant in myelofibrosis in the era of JAK inhibitors: a case-based review , 2019, Bone Marrow Transplantation.

[4] M. Sekeres,et al. Ruxolitinib Rechallenge Can Improve Constitutional Symptoms and Splenomegaly in Patients With Myelofibrosis: A Case Series , 2018, Clinical lymphoma, myeloma & leukemia.

[5] R. Latagliata,et al. Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients. , 2018, Leukemia research.

[6] P. Guglielmelli,et al. A life‐threatening ruxolitinib discontinuation syndrome , 2017, American journal of hematology.

[7] R. Fanin,et al. Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis , 2017, Oncotarget.

[8] M. Arcasoy,et al. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[9] K. Samii,et al. Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuation , 2014, International Journal of Hematology.

[10] R. Porcher,et al. Ruxolitinib Before Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) In Patients With myelofibrosis : a Preliminary Descriptive Report Of The JAK ALLO Study, a Phase II Trial Sponsored By Goelams-FIM In Collaboration With The Sfgmtc , 2013 .

[11] S. Barta,et al. Ruxolitinib withdrawal syndrome leading to tumor lysis. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12] Francisco Cervantes,et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. , 2012, The New England journal of medicine.

[13] A. Tefferi,et al. Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. , 2011, Mayo Clinic proceedings.

[14] Ayalew Tefferi,et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. , 2010, The New England journal of medicine.

[15] B. Preston,et al. Case Series , 2010, Toxicologic pathology.

[16] M. Cusini,et al. Case-based review , 2013 .